نتائج البحث - Andrzej Jakubowiak

تنقيح النتائج
  1. 1
    Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview

    Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview حسب Andrzej Jakubowiak

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Differential Effects of Gonadotropin-Releasing Hormone (GnRH) Pulse Frequency on Gonadotropin Subunit and GnRH Receptor Messenger Ribonucleic Acid Levels in Vitro*

    Differential Effects of Gonadotropin-Releasing Hormone (GnRH) Pulse Frequency on Gonadotropin Subunit and GnRH Receptor Messenger Ribonucleic Acid Levels in Vitro* حسب Ursula B. Kaiser, Andrzej Jakubowiak, Anna Steinberger, William W. Chin

    منشور في 1997
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Monoclonal antibodies in the treatment of multiple myeloma

    Monoclonal antibodies in the treatment of multiple myeloma حسب Paul G. Richardson, Sagar Lonial, Andrzej Jakubowiak, Jean‐Luc Harousseau, Kenneth C. Anderson

    منشور في 2011
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma حسب Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim Iskander, Khalid Mezzi, David S. Siegel

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis

    Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis حسب Benjamin A. Derman, Jagoda Jasielec, Spencer S. Langerman, Wei Zhang, Andrzej Jakubowiak, Brian C.‐H. Chiu

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

    Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous ste... حسب Benjamin A. Derman, Andrew Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda Jasielec, Andrzej Jakubowiak

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia

    Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia حسب Lisa Kujawski, Peter Ouillette, Harry P. Erba, Chris Saddler, Andrzej Jakubowiak, Mark Kaminski, Kerby Shedden, Sami N. Malek

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

    Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective حسب Andrzej Jakubowiak, Marco Campioni, Ágnes Benedict, Ivan Houisse, Eszter Tichy, Andromachi Giannopoulou, Sanjay Aggarwal, Beth Barber, Sumeet Panjabi

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

    Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) حسب Benjamin A. Derman, Ajay Major, Jennifer H. Cooperrider, Ken Jiang, Aubrianna Ramsland, Theodore Karrison, Tadeusz Kubicki, Andrzej Jakubowiak

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

    Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma حسب Andrzej Jakubowiak, Don M. Benson, William Bensinger, David S. Siegel, Todd M. Zimmerman, Ann Mohrbacher, Paul G. Richardson, Daniel Afar, Anil Singhal, Kenneth C. Anderson

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia

    A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia حسب Irene M. Ghobrial, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, Noopur Raje, Andrzej Jakubowiak, Michael R. Savona, Mihaela Obreja, Jesús G. Berdeja

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition

    Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition حسب Mikhail A. Nikiforov, MaryBeth Riblett, W. H. Wilson Tang, Vladimir Gratchouck, Dazhong Zhuang, Yolanda Fernández, Monique Verhaegen, Sooryanarayana Varambally, Arul M. Chinnaiyan, Andrzej Jakubowiak, Marı́a S. Soengas

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

    Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant حسب Benjamin A. Derman, Jennifer H. Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza Rampurwala, David R. Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, Andrzej Jakubowiak

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

    Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma حسب Andrzej Jakubowiak, Shaji Kumar, Rohan Medhekar, Huiling Pei, Patrick Lefèbvre, Shuchita Kaila, Jianming He, Marie‐Hélène Lafeuille, Annelore Cortoos, Anil Londhe, Panagiotis Mavros, Thomas S. Lin, Saad Z. Usmani

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

    Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with... حسب Noopur Raje, Andrzej Jakubowiak, Cristina Gasparetto, Robert F. Cornell, Heike I. Krupka, Daniel Navarro, Alison Forgie, Chandrasekhar Udata, Cynthia Basu, Jeffrey Chou, Abraham C.F. Leung, Alexander M. Lesokhin

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

    An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib... حسب Ravi Vij, David S. Siegel, Sundar Jagannath, Andrzej Jakubowiak, Alexander K. Stewart, Kevin T. McDonagh, Nizar J. Bahlis, Andrew R. Belch, Lori Kunkel, Sandra Wear, Alvin Wong, Robert Z. Orlowski, Michael Wang

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

    Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma حسب Sagar Lonial, Paul G. Richardson, Jesús F. San Miguel, Pieter Sonneveld, Michael W. Schuster, Joan Bladé, Jamie Cavenagh, S. Vincent Rajkumar, Andrzej Jakubowiak, Dixie‐Lee Esseltine, Kenneth C. Anderson, Jean‐Luc Harousseau

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor

    Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor حسب Shaun Rosebeck, Mattina M. Alonge, Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum, Jagoda Jasielec, Dominik Dytfeld, Sean P. Maxwell, Stephanie J. Kraftson, Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej Jakubowiak

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

    Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study حسب Jonathan L. Kaufman, Roberto Mina, Andrzej Jakubowiak, Todd L. Zimmerman, Jeffrey Wolf, Colleen Lewis, Charise Gleason, Cathy Sharp, Thomas G Martin, Leonard T. Heffner, Ajay K. Nooka, R. Donald Harvey, Sagar Lonial

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

    Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 حسب Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher Chanan‐Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej Jakubowiak, Steven D. Reich, Mohit Trikha, Kenneth C. Anderson

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: